Endra Life Sciences Inc (NDRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 762 | 3,230 | 2,834 | 4,889 | 9,462 |
| Inventories | N/A | N/A | N/A | 2,645 | 1,285 |
| TOTAL | $968 | $3,434 | $3,033 | $8,024 | $12,094 |
| Non-Current Assets | |||||
| PPE Net | 43 | 69 | 112 | 236 | 131 |
| Other Non-Current Assets | 2,843 | 949 | 3,610 | 1,014 | 649 |
| TOTAL | $2,886 | $1,019 | $3,721 | $1,250 | $781 |
| Total Assets | $3,854 | $4,452 | $6,754 | $9,274 | $12,875 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | N/A | N/A | 29 | 29 | N/A |
| Accounts payable and accrued liabilities | 622 | 508 | 701 | 1,523 | 1,411 |
| TOTAL | $751 | $605 | $903 | $1,704 | $1,544 |
| Non-Current Liabilities | |||||
| Long Term Debt | N/A | N/A | N/A | N/A | 29 |
| Other Non-Current Liabilities | 843 | 1,287 | 192 | 366 | 518 |
| TOTAL | $843 | $1,287 | $192 | $366 | $547 |
| Total Liabilities | $1,594 | $1,892 | $1,095 | $2,070 | $2,090 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 1,241 | 562 | 6 | 2 | 1 |
| Retained earnings | -110,466 | -103,438 | -91,930 | -81,870 | -68,691 |
| Other shareholders' equity | 0 | 0 | 5 | 6 | 14 |
| TOTAL | $2,260 | $2,560 | $5,659 | $7,205 | $10,784 |
| Total Liabilities And Equity | $3,854 | $4,452 | $6,754 | $9,274 | $12,875 |